A pair of early-stage developments highlighted how companies are converting platform science into near-term clinical execution. Regcell raised $66 million, including Japanese government support, to advance an epigenetic reprogramming Treg platform toward the clinic with an eye on converting disease-driving immune cells into antigen-specific regulatory T cells. Meanwhile, in immuno-metabolic product development, a seed-backed Aptadir Therapeutics closed a €40 million financing to advance RNA inhibitor-based therapeutics for genetic conditions including fragile X syndrome and myelodysplastic syndrome, underscoring the sustained capital availability for gene-expression targeting approaches. Together, the funding moves reflect continued emphasis on programmable immune modulation and RNA-based mechanisms that can be scaled through repeatable chemistry and delivery workflows.